Acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at the upcoming aacr-nci-eortc international conference on molecular targets and cancer therapeutics

Watertown, mass., sept. 19, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that two abstracts have been selected for poster presentations at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics, being held from october 11-15, 2023 in boston.
ACRV Ratings Summary
ACRV Quant Ranking